Profile: Biogen Idec Inc. is in the business of biotechnology. We focus mainly on oncology, neurology and immunology. Our core capabilities include drug discovery, research, development, biomanufacturing and a global commercial infrastructure. Our rituxan is indicated for the treatment of patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-hodgkin's lymphoma (NHL), which is a cancer of the lymphatic system. Our amevive is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The treatment is administered via IM injection once per week of 12 doses.